Bernard A. Fox, Co-founder, President, and CEO of UbiVac, shared a post on LinkedIn:
“Napoli – Here I Come!
This will be the 16th melanoma Bridge that Paolo A. Ascierto has organized. I attended the first and have only missed a couple. While they are always Amazing, I am really looking forward to this year’s meeting. As one of the meeting’s co-Presidents, I am very proud of the program. This is a small meeting with a large number of Incredible Experts, and everyone has the opportunity to speak with all of the presenters.
As for me, I will be talking about Cancer’s Dark Matter antigens! What I believe are the hottest topic in the cancer immunotherapy space!
These are Dark Genome-derived non-cannonical peptides. Some of these appear to have Driver-like function. Increasing their relevance as important cancer vaccine targets.
The recent cancer vaccine review by Samir Khleif and Seema Gupta in the October 2025 Nature Magazine Immunology Reviews does a great job covering the immunology of priming and reviews the Dark Matter antigen space as well as the 1st dark matter clinical trial.
Watch for a coming JITC Review on the topic (Wang and Fox).
Will also note that Vivenko does an amazing job taking care of the details.
Doors Closing!”
Proceed to the video attached to the post.
More posts featuring Bernard A. Fox.